Malarone — Competitive Intelligence Brief

Malarone (PROGUANIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial [EPC]. Area: Rare Disease.

marketed Antimalarial [EPC] Rare Disease Small molecule

Target snapshot

Malarone (PROGUANIL) — GSK. Malarone works by inhibiting the parasite's ability to synthesize nucleic acids, ultimately preventing its replication and spread within the body.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Malarone TARGET	PROGUANIL	GSK	marketed	Antimalarial [EPC]		2000-01-01
Coartem	ARTEMETHER		marketed	Antimalarial [EPC]		2009-01-01
Coartem	LUMEFANTRINE	Novartis	marketed	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Qualaquin	QUININE	Sun Pharm Industries	marketed	Antimalarial	Sodium channel alpha subunits; brain (Types I, II, III)	2005-01-01
Halfan	HALOFANTRINE	GSK	marketed	Antimalarial	Potassium voltage-gated channel subfamily H member 2	1992-01-01
Mepron	ATOVAQUONE		marketed	Antimalarial [EPC]	ATP-binding cassette sub-family G member 2	1992-01-01
Lariam	MEFLOQUINE HYDROCHLORIDE		marketed	Antimalarial	Adenosine receptor A2a	1989-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial [EPC] class)

1. · 2 drugs in this class
2. GSK · 1 drug in this class
3. Novartis · 1 drug in this class
4. State University of New York - Upstate Medical University · 1 drug in this class